2m 2m 2m 2m 2m 2m 2m
CAPRICOR THERAP (CAPR)
NASDAQ
$27.50+$0.16 (+0.59%)
Price as of Jun 03, 2026 7:09 PM EDT- $1.7BMarket Cap
- 145.20%1-Year Change
- BiotechnologyIndustry
CAPRICOR THERAP (CAPR)
$27.50+$0.16 (+0.59%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 0 -100.00% | 22.3M -11.55% | 25.2M +886.81% | 2.6M +941.85% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 -100.00% | 22.3M -11.55% | 25.2M +886.81% | 2.6M +941.85% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -84.5M +69.02% | -50.0M +37.10% | -36.4M +67.06% | -21.8M +60.76% | |
Depreciation and Amortization Expense | 1.9M +32.54% | 1.4M +33.34% | 1.1M +100.49% | 533,131 +116.99% | |
Total Operating Expenses | 108.1M +66.80% | 64.8M +31.63% | 49.3M +52.74% | 32.2M +52.24% | |
Operating Profit | -108.1M +154.06% | -42.6M +76.78% | -24.1M -18.92% | -29.7M +41.83% | |
Interest Income | 6.3M +184.05% | 2.2M +27.44% | 1.7M +231.46% | 521,535 +807.65% | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 6.3M +184.05% | 2.2M +27.44% | 1.7M +231.46% | 521,535 +807.65% | |
Total Nonoperating Income and Expense | 3.1M +47.77% | 2.1M +17.17% | 1.8M +164.12% | 677,851 -25.99% | |
Income before Taxes | -105.0M +146.78% | -42.6M +76.78% | -24.1M -18.92% | -29.7M +41.83% | |
Income Taxes | 1,600 N/A | N/A N/A | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -105.0M +159.58% | -40.5M +81.57% | -22.3M -23.20% | -29.0M +44.93% | |
Net Income from Continuing Operations Applicable to Common | -105.0M +159.57% | -40.5M +81.57% | -22.3M -23.20% | -29.0M +44.93% | |
Basic EPS and Net Income | -2.26 +96.52% | -1.15 +38.55% | -0.83 -29.66% | -1.18 +35.63% | |
Diluted EPS and Net Income | -2.26 +96.52% | -1.15 +38.55% | -0.83 -29.66% | -1.18 +35.63% | |
Basic Weighted Average Shares | 46.5M +31.97% | 35.2M +31.52% | 26.8M +9.06% | 24.6M +6.34% | |
Diluted Weighted Average Shares | 46.5M +31.97% | 35.2M +31.52% | 26.8M +9.06% | 24.6M +6.34% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 287.8M +2,450.26% | 11.3M -23.19% | 14.7M +53.02% | 9.6M -72.47% | |
Short-Term Investments | 30.3M -78.41% | 140.2M +465.60% | 24.8M -22.08% | 31.8M N/A | |
Cash and Cash Equivalents and Short-Term Investments | 318.1M +109.96% | 151.5M +283.70% | 39.5M -4.67% | 41.4M +18.74% | |
Total Current Assets | 322.9M +97.66% | 163.4M +221.27% | 50.9M +18.58% | 42.9M +17.71% | |
Accumulated Depreciation | 5.2M +49.29% | 3.5M +56.39% | 2.2M +86.70% | 1.2M +56.15% | |
Property and Plant and Equipment and Net | 18.3M +229.26% | 5.6M +0.02% | 5.6M +21.20% | 4.6M +155.50% | |
Total Long-Term Assets | 1.2M +423.00% | 221,700 -17.33% | 268,172 0.00% | 268,172 -2.74% | |
Total Assets | 355.9M +108.79% | 170.5M +190.26% | 58.7M +17.25% | 50.1M +21.21% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | 89,234 N/A | |
Total Current Liabilities | 35.8M +70.44% | 21.0M -32.76% | 31.3M +32.57% | 23.6M +470.63% | |
Total Long-Term Debt | N/A N/A | N/A N/A | 3.4M 0.00% | 3.4M 0.00% | |
Total Long-Term Liabilities | 14.3M +258.68% | 4.0M -17.90% | 4.9M -66.97% | 14.7M +152.57% | |
Total Liabilities | 50.2M +100.48% | 25.0M -30.76% | 36.1M -5.68% | 38.3M +284.54% | |
Retained Earnings | -304.9M +52.57% | -199.8M +25.39% | -159.4M +16.26% | -137.1M +26.85% | |
Total Stockholders Equity | 305.8M +110.22% | 145.5M +543.60% | 22.6M +91.76% | 11.8M -62.43% | |
Total Shares Outstanding | 57.4M +25.86% | 45.6M +46.34% | 31.1M +23.40% | 25.2M +4.37% | |
Cash Flow | |||||
Cash from Operating Activities | -69.8M +74.55% | -40.0M +56.25% | -25.6M -620.61% | 4.9M +129.25% | |
Capital Expenditures | 2.9M +148.91% | 1.2M -11.04% | 1.3M -34.42% | 2.0M +67.20% | |
Cash from Investing Activities | 97.5M +183.90% | -116.2M -2,374.45% | 5.1M +114.56% | -35.1M +2,831.78% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 248.9M +62.92% | 152.8M +497.23% | 25.6M +424.84% | 4.9M -75.90% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | -191.13% +99.86% | -95.63% -91.78% | -1,163.93% -86.39% | |
Return on Assets | -39.91% +13.02% | -35.31% -13.79% | -40.96% -35.48% | -63.48% +20.40% | |
Return on Equity | -46.56% -3.32% | -48.16% -62.85% | -129.63% -3.62% | -134.49% +100.06% | |
Revenue Growth | -100.00% +765.94% | -11.55% -101.30% | 886.81% -5.84% | 941.85% +4,571.31% | |
Current Ratio | 9.01 +15.97% | 7.77 +377.81% | 1.63 -10.56% | 1.82 -79.37% | |
Cash Ratio | 8.03 +1,396.31% | 0.54 +14.24% | 0.47 +15.43% | 0.41 -95.18% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | 0.29 +173.23% | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | 0.07 -15.30% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow